60 Chapter 3 REFERENCES 1. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. Sep 2016;27(suppl 5):v58-v68. doi:10.1093/annonc/mdw328 2. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. Aug 1999;17(8):2530-40. doi:10.1200/JCO.1999.17.8.2530 3. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. Dec 01 2009;27(34):5794-9. doi:10.1200/JCO.2008.21.4809 4. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. May 1 2014;370(18):1769-70. doi:10.1056/NEJMc1400731 5. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. British journal of urology. Feb 1989;63(2):128-31. doi:10.1111/j.1464-410x.1989.tb05147.x 6. Harrison MR, Costello BA, Bhavsar NA, et al. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. Jul 1 2021;127(13):2204-2212. doi:10.1002/cncr.33494 7. Bimbatti D, Ciccarese C, Fantinel E, et al. Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urol Oncol. Dec 2018;36(12):526 e13-526 e18. doi:10.1016/j.urolonc.2018.08.018 8. Matsubara N, Mukai H, Naito Y, Itoh K, Komai Y, Sakai Y. First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma. Urology. Jul 2013;82(1):118-23. doi:10.1016/j. urology.2013.03.035 9. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The Lancet Oncology. 2016;17(9):1317-1324. doi:10.1016/s1470-2045(16)30196-6 10. Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927;8(6):519530. doi:10.1085/jgp.8.6.519 11. Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer science. Mar 2013;104(3):275-81. doi:10.1111/cas.12085 12. Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. American journal of clinical pathology. Dec 2010;134(6):873-9. doi:10.1309/ajcpppr57hnjmslz 13. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. Jul 2010;58(1):75-83. doi:10.1016/j.eururo.2010.03.015 14. Kayani I, Avril N, Bomanji J, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. Sep 15 2011;17(18):6021-8. doi:10.1158/1078-0432.CCR-10-3309 15. Brouwers AH, Dorr U, Lang O, et al. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun. Mar 2002;23(3):22936. 16. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 2007;25(30):4757-4764. doi:10.1200/ jco.2007.12.1087 17. Ambrosetti D, Dufies M, Dadone B, et al. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma. PLoS One. 2018;13(2):e0193477. doi:10.1371/journal.pone.0193477 18. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. Feb 2003;9(2):802-11. 19. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. Sep 2007;100(3):556-60. doi:10.1111/j.1464410X.2007.07006.x 20. Zhao Z, Liao G, Li Y, Zhou S, Zou H, Fernando S. Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature. PLoS ONE. 11/26/05/23/received 10/30/ accepted 2014;9(11):e114096. doi:10.1371/journal.pone.0114096\
RkJQdWJsaXNoZXIy MTk4NDMw